Common questions about Biopolio (FAQ)
Q: What is the main difference between Biopolio Oral Vaccine and the injectable polio vaccine (IPV)?
A: Official information indicates that Biopolio is a live, attenuated vaccine given orally, which means it uses weakened polioviruses. It helps create immunity in both the blood and the gut, which is considered essential for helping to limit the spread of the virus within a community. The injectable polio vaccine (IPV) is an inactivated vaccine; it is given as a shot, induces immunity mainly in the blood, and carries no risk of vaccine-associated paralysis.
Q: Why is Biopolio administered orally as drops, and how does that affect its effectiveness?
A: Biopolio is a live, attenuated vaccine administered orally as drops. Official product information states that this route of administration helps stimulate immune responses in both the blood and the gut lining (mucosal immunity). The gut immunity it creates is vital for helping to reduce the ability of the poliovirus to multiply in the intestines.
Q: Is Biopolio the same as the bivalent Oral Polio Vaccine (bOPV)?
A: Yes, regulatory information confirms that Biopolio B1/3 is a trade name for a Bivalent Oral Poliomyelitis Vaccine (bOPV). This means it contains live, weakened poliovirus strains for Type 1 and Type 3.
Q: Is Biopolio considered a 'live' vaccine or an 'inactivated' vaccine?
A: According to the official product classification, Biopolio is a live, attenuated vaccine. It is made from weakened strains of poliovirus (Sabin strains) which is designed to replicate in the gut but generally does not cause poliomyelitis disease.
Q: What happens if a child vomits shortly after receiving the Biopolio drops?
A: Official administration guidelines state that if a child experiences vomiting or diarrhea shortly after receiving the oral drops, that specific dose should not be counted as part of their immunization schedule. The official administration procedure states that this dose should be repeated after the child recovers.
Q: Why do some people receive Biopolio while others receive an inactivated polio shot?
A: The use of both the oral vaccine (Biopolio) and the inactivated shot (IPV) is part of a global immunization strategy. The oral vaccine is essential for developing local immunity in the gut to reduce transmission. The IPV shot is highly effective at preventing the virus from reaching the central nervous system to cause paralysis.
Q: What is the risk of vaccine-associated paralysis (VAPP) with Biopolio?
A: Vaccine-associated paralytic poliomyelitis (VAPP) is a very rare adverse event that is associated with oral polio vaccines. Official data indicates that VAPP is an extremely rare event, occurring in a very small fraction of total doses given, typically after the first dose. Inactivated polio vaccine (IPV) does not carry this risk.
Q: How does Biopolio contribute to global polio eradication efforts?
A: Official documents highlight that Biopolio is a critical tool because of its ability to establish immunity in the gut lining. This action helps to reduce the ability of the virus to multiply and, consequently, aids in interrupting the person-to-person spread of the virus throughout the community, which is essential for eradication.
Q: What is the function of the Vaccine Vial Monitor (VVM) found on the Biopolio label?
A: The Vaccine Vial Monitor (VVM) is a small, heat-sensitive indicator dot found on the vaccine label. Its function is to monitor the cumulative heat exposure of the vial. This provides a visual signal, indicating when excessive heat may have compromised the vaccine's potency, which helps to ensure that only effective vaccine is administered.
Q: How long can an opened multi-dose vial of Biopolio be used if stored correctly?
A: According to the official storage instructions, an opened multi-dose vial of Biopolio (bOPV) can be used for a maximum of 28 days (4 weeks) after the initial opening. This is contingent on the vial having been continuously stored between 2 C and 8 C, and the Vaccine Vial Monitor (VVM) still showing the vaccine is acceptable for use.
Q: Can Biopolio be given to a child who has previously received the injectable polio vaccine?
A: Official guidelines confirm that previous vaccination with the inactivated polio vaccine (IPV) is not a contraindication for receiving a dose of Biopolio (bOPV). These vaccines are often used in combination as part of the overall immunization strategy.
Q: What is the difference between the trivalent and bivalent Biopolio formulations?
A: The original trivalent oral polio vaccine (tOPV) contained weakened poliovirus strains for Types 1, 2, and 3. The current bivalent formulation (Biopolio/bOPV) only contains strains for Types 1 and 3. This change was implemented as part of a global strategy to phase out the Type 2 component.
Q: What is the purpose of giving Biopolio multiple times in a child's immunization schedule?
A: Official clinical trial documents indicate that the multiple doses are administered to achieve and maintain strong protective immunity. The goal of repeating the doses is to promote the development of strong, protective antibody levels (known as seroconversion) in the child.
Q: Does Biopolio offer lifelong immunity or are boosters needed later in life?
A: The need for long-term boosters is not explicitly stated in regulatory labels. The vaccine is designed to induce a sustained immune response to help meet the objectives of the Global Polio Eradication Initiative.
Q: What are the signs of a severe allergic reaction to Biopolio that I should watch for?
A: The vaccine is officially contraindicated in individuals with a known hypersensitivity to any of its components, such as neomycin or kanamycin. While the specific physical signs of an allergic reaction are not detailed in all product labels, any suspected sign of a severe reaction should be reported immediately to a healthcare provider.
Q: Does the use of antibiotics affect how well the Biopolio vaccine works?
A: Official labeling confirms that the vaccine itself contains trace antibiotics used in manufacturing. However, the product information does not specify that a patient's concurrent therapeutic use of systemic antibiotics will reduce the protective effectiveness of the vaccine.
Q: Why is the Biopolio vaccine only available in certain regions or countries?
A: Biopolio (bOPV) is primarily indicated for use in areas where there is a risk of poliovirus transmission, including endemic areas, to support global eradication efforts. Its availability is focused on supporting the specific epidemiological needs of these regions.
Q: What kind of research evidence supports the safety and effectiveness of Biopolio?
A: Biopolio has been prequalified by the World Health Organization (WHO), a process that ensures it meets established global standards for safety and effectiveness. Clinical studies have demonstrated its capacity to provide active immunization and generate protective antibodies against the targeted poliovirus types.
Q: What are the recommendations for travelers regarding the Biopolio vaccine?
A: Global health organizations indicate that the oral polio vaccine (OPV/bOPV) may be administered to travelers, regardless of age, who are visiting areas known to be infected with wild poliovirus or circulating vaccine-derived poliovirus. This use is intended to assist in providing protection against the risk of infection.
Q: How does the vaccine prevent the spread of the poliovirus to the central nervous system?
A: In response to the vaccine, the body produces protective antibodies that circulate in the blood (a systemic response known as humoral immunity). Official information states that these blood-borne antibodies are crucial for neutralizing the virus and preventing it from reaching the central nervous system, which is where paralysis can occur.
Q: Is the formulation of Biopolio B1/3 liquid or powder?
A: Biopolio B1/3 is supplied as a liquid suspension in a vial. It is designed to be administered orally as drops directly into the mouth.
Q: Why is it important to keep children's immunizations up-to-date with Biopolio?
A: Adhering to the recommended schedule is important because the vaccine is a vital component of the global effort to eliminate polio. Keeping immunizations up-to-date ensures that the child is protected and that the vaccine is effective in reducing the risk of viral spread within the community.
Q: What are the side effects for adults who might receive Biopolio (if applicable)?
A: For adults, the official product information reports that no side effects are observed in the vast majority of cases. If reactions do occur, they are generally mild and transient, similar to those that might affect the gastrointestinal tract.
Q: What ingredients are included in the Biopolio vaccine besides the poliovirus components?
A: Official product information lists the active ingredients as the Type 1 and Type 3 poliovirus Sabin strains. It also contains Magnesium Chloride as a stabilizer, and trace amounts of antibiotics such as Kanamycin Acid Sulphate and Neomycin Sulphate.
